Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Naphazoline + pheniramine** is an ophthalmic combination drug containing a sympathomimetic vasoconstrictor (naphazoline) and a first-generation antihistamine (pheniramine). It is used as eye drops for the temporary relief of itching and redness associated with allergic conjunctivitis. - **Naphazoline** acts by constricting the blood vessels in the eye, thereby reducing redness and swelling. It is classified as a sympathomimetic amine (vasoconstrictor/decongestant). - **Pheniramine** is an H1 histamine receptor antagonist that blocks the action of histamine released during allergic reactions, relieving itching and irritation[1][3][6]. The combination is available over-the-counter and was first approved for clinical use in the United States in 1994[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naphazoline + pheniramine.